February 2024—Fujirebio announced the availability of its Lumipulse G pTau 217 plasma assay for the fully automated Lumipulse G immunoassay systems. The chemiluminescent enzyme immunoassay provides a quantitative measurement of pTau 217 in human K2EDTA plasma within 35 minutes. The assay is for research use only.
Read More »Home >> Tag Archives: Fujirebio
Fujirebio, Janssen team up
July 2018—Fujirebio has entered into an agreement with Janssen Pharmaceuticals to develop and commercialize an amyloid β 42/40 ratio assay. The assay will run on the Lumipulse series
Read More »